Full Press Release Details
Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd
American Society of Hematology Annual Meeting
presentations highlight lead candidate loncastuximab tesirine (Lonca); BLA under FDA review for the treatment of relapsed or refractory
diffuse large B-cell lymphoma
preliminary data from pivotal Phase 2 trial of camidanlumab tesirine (Cami) in Hodgkin lymphoma selected for oral presentation
to host virtual investor event on December 7, 2020 at 8 am ET
Lausanne, Switzerland, November
4, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering
the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological
malignancies and solid tumors, today announced that eight abstracts have been selected for presentation at the 62nd
American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020. Presentations will
feature data on three of the Company's pyrrolobenzodiazepine (PBD)-based ADCs - loncastuximab tesirine (Lonca), camidanlumab
tesirine (Cami) and ADCT-602.
"The breadth of data that
will be presented at the ASH Annual Meeting reflects the potential of our product candidates and speaks to our leadership in the
development of next-generation ADCs to improve outcomes for patients with blood cancers," said Jay Feingold, MD, PhD, Senior
Vice President and Chief Medical Officer of ADC Therapeutics. "Notably, we look forward to sharing subgroup data from the
Lonca LOTIS 2 pivotal trial in relapsed or refractory diffuse large B-cell lymphoma, interim results from our LOTIS 3 trial evaluating
Lonca in combination with ibrutinib in patients with advanced diffuse large B-cell lymphoma or mantle cell lymphoma, as well as
preliminary results from our pivotal Phase 2 trial of Cami in patients with relapsed or refractory Hodgkin lymphoma."
Efficacy and Safety of Loncastuximab
Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Date and Time: Saturday,
December 5, 2020, 7 a.m. - 3:30 p.m. PST
Session: 626. Aggressive
Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials:
Presenter: Paolo F. Caimi,
MD, Case Comprehensive Cancer Center, Case Western Reserve University
Characteristics and Treatment
Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received 3 Lines of Therapies
Date and Time: Saturday,
December 5, 2020, 7 a.m. - 3:30 p.m. PST
Session: 905. Outcomes
Research-Malignant Conditions (Lymphoid Disease): Poster I
Presenter: Jipan Xie, MD,
PhD, Analysis Group, Inc.
Interim Results of Loncastuximab
Tesirine Combined with Ibrutinib in Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
Date and Time: Sunday,
December 6, 2020, 7 a.m. - 3:30 p.m. PST
Session: 626. Aggressive
Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials:
Presenter: Julien Depaus,
Safety and Antitumor Activity
Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma
Date and Time: Sunday,
December 6, 2020, 7 a.m. - 3:30 p.m. PST
Session: 626. Aggressive
Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials:
Presenter: Yuliya Linhares,
MD, Miami Cancer Institute, Baptist Health South Florida
Preliminary Results of a Phase
2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed
or Refractory Hodgkin Lymphoma
Date and Time: Sunday,
December 6, 2020, 3 p.m. PST
Session: 624. Hodgkin Lymphoma
and T/NK Cell Lymphoma-Clinical Studies: Clinical Studies in Hodgkin Lymphoma
Presenter: Alex Herrera,
MD, City of Hope Medical Center
Pharmacokinetic and Pharmacodynamic
Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and
Non-Hodgkin Lymphoma
Date and Time: Monday,
December 7, 2020, 7 a.m. - 3:30 p.m. PST
Session: 624. Hodgkin Lymphoma
and T/NK Cell Lymphoma-Clinical Studies: Poster III
Presenter: Joseph Boni,
Combination of Camidanlumab
Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models
Date and Time: Saturday,
December 5, 2020, 7 a.m. - 3:30 p.m. PST
Session: 625. Lymphoma:
Pre-Clinical-Chemotherapy and Biologic Agents: Poster I
Presenter: Francesca Zammarchi,
ADCT-602 Presentation
Analysis of Adct-602 Pre-Clinical
Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity
Date and Time: Monday,
December 7, 2020, 7 a.m. - 3:30 p.m. PST
Session: 625. Lymphoma:
Pre-Clinical-Chemotherapy and Biologic Agents: Poster III
Presenter: Francesco Bertoni,
MD, Institute of Oncology Research, Universit della Svizzera italiana
Online Publication in November
Supplemental Issue of Blood
Symptoms, Health-Related Quality
of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma
Abstract Number: 3919
The abstracts are available through
the ASH online meeting program and will be published in the November supplemental issue of Blood.
About Loncastuximab Tesirine
Loncastuximab tesirine (Lonca,
formerly ADCT-402) is an antibody drug conjugate (ADC) composed of a humanized monoclonal antibody directed against human CD19
and conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. Once bound to a CD19-expressing cell, Lonca
is designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly
to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic
processes such as replication and ultimately resulting in cell death. CD19 is a clinically validated target for the treatment
of B-cell malignancies.
In September 2020, ADC Therapeutics